457669AA7

Insmed Incorporated

Could not find a ticker for this position, may be a filing error

A maker of inhaled medicines for rare lung diseases, Insmed sells ARIKAYCE for a stubborn bacterial lung infection and BRINSUPRI for bronchiectasis, with gene therapies for muscular dystrophy and ALS in the works. Founded in 1988 in Richmond, Virginia, it began by developing insulin-like growth factor proteins before turning to respiratory care. Its ARIKAYCE was the first drug approved under the FDA's Limited Population Pathway, designed for serious infections in small patient groups.

1.75% Convertible Senior Notes due 2025, redeemed August 9, 2024